Testing efgartigimod for acute NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a drug called efgartigimod for people having a sudden worsening of NMOSD symptoms. It targets a protein to reduce attack severity and is given alongside standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have a confirmed diagnosis of NMOSD with positive AQP4 antibodies
- Be having an acute attack that affects the optic nerve or spinal cord
- Have a moderate to severe disability level (EDSS score 2.5–7.5) during the attack
- Agree to stop other immunosuppressive drugs before starting the study
- Have new or actively inflamed lesions on an MRI scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial tests a new medicine called inectolizumab, combined with optimized steroid therapy, for people having their first attack of neuromyelitis optica spectrum disorder (NMOSD). The goal is to see if this combination better controls the disease and prevents future attacks.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.